BBIO (STOCKS)
BridgeBio Pharma, Inc. Common Stock
$79.580000
-4.260000 (-5.08%)
Prev close: $83.840000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Neil Kumar
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $16,649.99M
- Employees
- 730
- P/E (TTM)
- -22.76
- P/B (TTM)
- -6.31
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
6
Strong Buy
19
Buy
3
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2026 (Q2)
|
$-0.78 | $-0.60 | -0.1849 | -31.07% |
|
Mar 2026 (Q1)
|
$-0.84 | $-0.69 | -0.1479 | -21.37% |
|
Dec 2025 (Q4)
|
$-1.00 | $-0.76 | -0.2430 | -32.10% |
|
Sep 2025 (Q3)
|
$-0.95 | $-0.91 | -0.0436 | -4.81% |
Financial Statements
| Revenues | $713.07M |
| Benefits Costs and Expenses | $1.42B |
| Cost Of Revenue | $39.66M |
| Costs And Expenses | $1.21B |
| Gross Profit | $673.41M |
| Nonoperating Income/Loss | -$205.89M |
| Operating Expenses | $1.17B |
| Selling, General, and Administrative Expenses | $645.86M |
| Research and Development | $505.38M |
| Operating Income/Loss | -$497.80M |
| Income/Loss Before Equity Method Investments | -$642.10M |
| Income/Loss From Continuing Operations After Tax | -$702.02M |
| Income/Loss From Continuing Operations Before Tax | -$703.68M |
| Income/Loss From Equity Method Investments | -$61.58M |
| Income Tax Expense/Benefit | -$1.67M |
| Net Income/Loss | -$702.02M |
| Net Income/Loss Attributable To Noncontrolling Interest | -$10.15M |
| Net Income/Loss Attributable To Parent | -$691.87M |
| Net Income/Loss Available To Common Stockholders, Basic | -$691.87M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$3.56 |
| Diluted Earnings Per Share | -$3.56 |
| Basic Average Shares | 391,771,002 |
| Diluted Average Shares | 391,771,002 |
| Assets | $1.22B |
| Current Assets | $1.09B |
| Inventory | $52.84M |
| Other Current Assets | $1.04B |
| Noncurrent Assets | $124.16M |
| Fixed Assets | $5.23M |
| Intangible Assets | $26.64M |
| Other Non-current Assets | $92.29M |
| Liabilities | $3.72B |
| Current Liabilities | $890.65M |
| Accounts Payable | $27.20M |
| Wages | $49.98M |
| Other Current Liabilities | $813.47M |
| Noncurrent Liabilities | $2.83B |
| Long-term Debt | $2.65B |
| Other Non-current Liabilities | $179.67M |
| Redeemable Noncontrolling Interest | -$1.02M |
| Equity | -$2.50B |
| Equity Attributable To Noncontrolling Interest | $10.34M |
| Equity Attributable To Parent | -$2.52B |
| Temporary Equity | -$1.02M |
| Liabilities And Equity | $1.22B |
| Net Cash Flow From Operating Activities | -$434.37M |
| Net Cash Flow From Operating Activities, Continuing | -$434.37M |
| Net Cash Flow From Investing Activities | -$34.74M |
| Net Cash Flow From Investing Activities, Continuing | -$34.74M |
| Net Cash Flow From Financing Activities | $398.05M |
| Net Cash Flow From Financing Activities, Continuing | $398.05M |
| Net Cash Flow | -$71.06M |
| Net Cash Flow, Continuing | -$71.06M |
| Comprehensive Income/Loss | -$702.03M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | -$10.15M |
| Comprehensive Income/Loss Attributable To Parent | -$691.87M |
| Other Comprehensive Income/Loss | -$8.00K |